A Phase II/III Randomized Clinical Trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence: PURITY Study
Latest Information Update: 30 Apr 2024
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Capecitabine
- Indications Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- Acronyms PURITY
Most Recent Events
- 08 Apr 2024 Trial design, published in the BMC Cancer
- 13 Nov 2023 Status changed from not yet recruiting to recruiting.
- 19 Sep 2023 New trial record